{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-062003","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2023-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.348926+00:00","generated_at":"2026-06-08T07:14:23.659162+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Erasca Q3 net loss $30.4M ($0.20/shr); cash $343.6M; first patient dosed in SEACRAFT-1","bullets":["Net loss $30.4M ($0.20/shr) vs $35.5M ($0.29/shr) in Q3 2022; decrease in R&D expenses to $25.2M.","Cash, equivalents, and marketable securities $343.6M at Sep 30, 2023, down from $435.6M at Dec 31, 2022; runway into H2 2025.","First patient dosed in SEACRAFT-1 Phase 1b (naporafenib + trametinib) for RAS Q61X solid tumors in Aug 2023.","Upcoming catalysts: SEACRAFT-1 initial data H2 2024; SEACRAFT-2 Phase 3 start H1 2024; HERKULES-3 expansion data H2 2023-H1 2024.","THUNDERBBOLT-1 initial Phase 1 monotherapy data in recurrent GBM expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-062003","json":"https://secwatch.observer/filing/0000950170-23-062003.json","markdown":"https://secwatch.observer/filing/0000950170-23-062003.md","text":"https://secwatch.observer/filing/0000950170-23-062003.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/0000950170-23-062003-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/eras-20231109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T07:14:23.659162+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd82e003339e79745f6e365cd396ad2bff58ef45","claim":"Erasca, Inc. reported the quarter ended September 30, 2023 results: net income Net loss was $30.4 million, or $(0.20) per basic and diluted share, EPS $(0.20) per basic and diluted share.","evidence_excerpt":"Erasca Reports Third Quarter 2023 Financial Results and Business Updates","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017023062003/0000950170-23-062003-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2023"},{"label":"Net income","value":"Net loss was $30.4 million, or $(0.20) per basic and diluted share"},{"label":"EPS","value":"$(0.20) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}